Intellia Therapeutics Announces Upcoming Lonvoguran Ziclumeran (Lonvo-z) Investor Event and Seven Presentations at ACAAI 2026
Intellia announced seven presentations (two oral, five poster) on lonvo-z at the ACAAI 2026 meeting, November 12-16 in Phoenix, including four-year durability/safety data from patients who received a one-time 50 mg dose. The company will host an investor webcast on November 12 at 10 a.m. ET to review the data and discuss preparations for a planned commercial launch of lonvo-z in hereditary angioedema.
Key figures
- Dose
- 50 mg one-time dose of lonvo-z
- Pdufa date
- March 10, 2027
- Webcast datetime
- November 12, 2026, 10 a.m. ET
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.